COVID-19 Complications in a Newly Diagnosed HIV Patient: A Case of Multiple Herpesvirus Reactivation and HLH Post-ART Initiation

Patient: Male, 47-year-old Final Diagnosis: COVID pneumonia • hemophagocytic lymphohistiocytosis (HLH) • HIV infection • Kaposi sarcoma Symptoms: Fever • hepatomegaly • renal failure • respiratory distress • skin lesion Clinical Procedure: — Specialty: Infectious Diseases Objective: Rare coexistence of disease or pathology Background: Hemophagocytic lymphohistiocytosis (HLH) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can trigger profound immune activation and systemic inflammation, leading to severe, often fatal, conditions. Simultaneously, HIV-infected patients, prone to immune dysregulation, face an increased risk of severe complications from SARS-CoV-2. The optimal timeline for initiating antiretroviral therapy (ART) in patients with severe SARS-CoV-2 and HIV co-infection, especially concerning the risk of HLH, remains uncertain. Case Report: We detail the case of a 47-year-old male with previously undiagnosed HIV who, following ART initiation, developed HLH amid SARS-CoV-2 co-infection. The patient also had biopsy-proven Kaposi Sarcoma with immunoreactivity to Human Herpesvirus 8 (HHV-8), detectable peripheral blood Epstein Barr virus (EBV) DNA PCR and Cytomegalovirus (CMV) DNA PCR, and suspected Pneumocystis jirovecii pneumonia. We believe these conditions contributed to the development of HLH. This case represents a unique report of multiple herpesviruses reactivation, acquired HLH during COVID-19 in a patient with previously undiagnosed HIV. Despite receiving ART, steroids, and appropriate antimicrobial therapy, the patient’s condition did not improve. Conclusions: Further research is required to understand immune dysregulation, including HLH, in patients with HIV and SARSCoV-2 co-infection. The effects of ART initiation on treatment-naïve patients with potential concurrent opportunistic infections and/or herpesvirus reactivation warrant deeper examination to formulate clinical guidelines.

[1]  D. Barouch,et al.  Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome , 2021, IDCases.

[2]  Sneha Suresh,et al.  Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis , 2021, International journal of molecular sciences.

[3]  S. Chamorro,et al.  Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore , 2021, Journal of Clinical Pathology.

[4]  A. Moreau,et al.  High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19 , 2021, Infectious Diseases Now.

[5]  J. Roliński,et al.  Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? , 2020, BMC Medicine.

[6]  R. Benjamin,et al.  Secondary HLH is uncommon in severe COVID‐19 , 2020, British journal of haematology.

[7]  T. Tarrant,et al.  Is the HScore useful in COVID-19? , 2020, The Lancet.

[8]  G. Chowell,et al.  Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[10]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[11]  Vinicius Jorge,et al.  Hemophagocytic Lymphohistiocytosis: Management and Special Consideration in Human Immunodeficiency Virus Positive Patients with Immune Reconstitution Syndrome , 2019, Cureus.

[12]  S. Aleem,et al.  A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults , 2017, Journal of Clinical Immunology.

[13]  M. Tesher,et al.  An Overview of Hemophagocytic Lymphohistiocytosis. , 2017, Pediatric annals.

[14]  M. Lazanas,et al.  Successful Treatment of immune Reconstitution Inflammatory syndrome-related Hemophagocytic Syndrome in an HIV Patient with Primary Effusion Lymphoma , 2016, Hematology reports.

[15]  É. Azoulay,et al.  Diversity and combinations of infectious agents in 38 adults with an infection-triggered reactive haemophagocytic syndrome: a multicenter study. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  A. Schram,et al.  How I treat hemophagocytic lymphohistiocytosis in the adult patient. , 2015, Blood.

[17]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[18]  P. Newburger,et al.  Advances in understanding the pathogenesis of HLH , 2013, British journal of haematology.

[19]  Yao-Hsu Yang,et al.  Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases , 2012, Clinical Rheumatology.

[20]  Simon Wandel,et al.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.

[21]  H. Albrecht,et al.  Viral infections associated with haemophagocytic syndrome , 2010, Reviews in medical virology.

[22]  S. Geerlings,et al.  Immune reconstitution inflammatory syndrome: immunopathogenesis, risk factors, diagnosis, treatment and prevention. , 2009, The Netherlands journal of medicine.

[23]  D. Heine-Suñer,et al.  Association of Monoclonal Expansion of Epstein-Barr Virus-Negative CD158a+ NK Cells Secreting Large Amounts of Gamma Interferon with Hemophagocytic Lymphohistiocytosis , 2008, Clinical and Vaccine Immunology.

[24]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[25]  H. Takada,et al.  Increased IL-16 Levels in Hemophagocytic Lymphohistiocytosis , 2004, Journal of pediatric hematology/oncology.

[26]  P. Marrack,et al.  An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. , 2004, Blood.

[27]  J. Piette,et al.  Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. , 2003, Arthritis and rheumatism.

[28]  D. Musher,et al.  Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral Therapy , 2002, Medicine.

[29]  J. Henter.  Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. , 2002, Medical and pediatric oncology.

[30]  D. Fisman.  Hemophagocytic syndromes and infection. , 2000, Emerging infectious diseases.

[31]  R. Pomerantz,et al.  Inflammatory Reactions in HIV-1Infected Persons after Initiation of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[32]  B. Gazzard,et al.  Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. , 1999, AIDS research and human retroviruses.

[33]  J. Henter,et al.  Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. , 1998, Hematology/oncology clinics of North America.

[34]  Daishi Tian,et al.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China , 2020 .